US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PIMCO DYNAMIC INCOME STRATEGY FUND

24.87

+0.14000.57%

Post-market: 25.000.1299+0.52%17:38 EDT

Volume:156.15K

Turnover:3.88M

Market Cap:1.11B

PE:14.21

High:25.00

Open:24.89

Low:24.69

Close:24.73

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

ACCESS Newswire

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PDX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PDX\",,,,,undefined,":{"symbol":"PDX","market":"US","secType":"STK","nameCN":"PIMCO DYNAMIC INCOME STRATEGY FUND","latestPrice":24.87,"timestamp":1749844800000,"preClose":24.73,"halted":0,"volume":156149,"hourTrading":{"tag":"盘后","latestPrice":24.9999,"preClose":24.87,"latestTime":"17:38 EDT","volume":207,"amount":5173.08,"timestamp":1749850688376},"delay":0,"floatShares":0,"shares":44706949,"eps":1.75078,"marketStatus":"Market Closed","change":0.14,"latestTime":"06-13 16:00:00 EDT","open":24.89,"high":25,"low":24.69,"amount":3880767.3494240004,"amplitude":0.012535,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.75078,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1548824400000,"exchange":"NYSE","adjPreClose":24.73,"dividendRate":0.073583,"postHourTrading":{"tag":"盘后","latestPrice":24.9999,"preClose":24.87,"latestTime":"17:38 EDT","volume":207,"amount":5173.08,"timestamp":1749850688376},"volumeRatio":1.7188961976537065},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PDX\",,,,,undefined,":{"symbol":"PDX","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.7188961976537065,"shares":44706949,"dividePrice":1.83,"high":25,"amplitude":0.012535,"preClose":24.73,"low":24.69,"week52Low":19.26,"pbRate":"--","week52High":32.8807,"institutionHeld":0,"latestPrice":24.87,"eps":1.75078,"divideRate":0.073583,"volume":156149,"delay":0,"ttmEps":1.75078,"open":24.89,"prevYearClose":26.13,"prevWeekClose":24.08,"prevMonthClose":23.25,"prevQuarterClose":24.54,"fiveDayClose":24.08,"twentyDayClose":22.34,"sixtyDayClose":23.98},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PDX\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PDX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535084331","title":"Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535084331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535084331?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166700,"startTime":"0","endTime":"0","summary":"-- SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia  Xenograft Models --. -- Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in AML Anticipated in 2025 --. -- $28.4 million in Cash and Cash Equivalents as of March 31, 2025; Additional $4.0 million Proceeds received in April 2025 through Warrant Exercises --. NEW YORK, May 13, 2025  -- SELLAS Life Sciences Group, Inc.  , a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.Presented Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference: Preclinical data suggest tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU1699723380.USD","ALL","PR","LU1571399168.USD","BK4585","PDX","OS","BK4139","BK4161","R","ORR","BK4588","CR","BK4022","BK4097","BK4107","BK4232","BK4213","SLS","LU0985320562.USD","LU2355687059.USD"],"gpt_icon":0},{"id":"2532366308","title":"PIMCO Closed-End Funds Declare Monthly Common Share Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2532366308","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532366308?lang=en_us&edition=fundamental","pubTime":"2025-05-02 05:14","pubTimestamp":1746134040,"startTime":"0","endTime":"0","summary":"Fund Distribution Information as of March 31, 2025:. Annualized current distribution rate expressed as a percentage of NAV as of 3/31/2025. Annualized current distribution rate expressed as a percentage of Market Price as of 3/31/2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pimco-closed-end-funds-declare-211400749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4595","BK4516","PNF","RCS","PDO","PNI","PFL","PFN","PDI","PYN","BK4585","BK4600","PCN","BK4588","PZC","PCK","BK4023","BK4596","PCM","STRK","PAXS","PCQ","PMF","PDX","PML","PGP","PMX","PTY","PHK"],"gpt_icon":1},{"id":"2530780282","title":"Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House","url":"https://stock-news.laohu8.com/highlight/detail?id=2530780282","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530780282?lang=en_us&edition=fundamental","pubTime":"2025-04-28 21:45","pubTimestamp":1745847900,"startTime":"0","endTime":"0","summary":"HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology , a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft  models.This comprehensive program will support drug developers across a range of modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/champions-oncology-obtains-radioactive-materials-134500788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSBR","ARKG","BK4121","PDX","BK4585","BK4544","BK4588"],"gpt_icon":0},{"id":"2530027654","title":"Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2530027654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530027654?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:28","pubTimestamp":1745843280,"startTime":"0","endTime":"0","summary":"Activated b-catenin or loss of its negative regulator adenomatous polyposis coli  is a potential biomarker for NT219 in the treatment of colorectal cancer. NT219’s mechanism of action informs how it can restore efficacy of immunotherapies and expand the patient population that can benefit from immunotherapies. REHOVOT, Israel, April 28, 2025  -- Purple Biotech Ltd.  , a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today that two posters reporting new NT219 data being presented at the American Association for Cancer Research  Annual Meeting on Sunday and Monday, April 27-28, 2025.NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or metastatic head and neck squamous cell cancer  in combination with pembrolizumab  and in combination with cetuximab .“These biomarker and mechanism data are important guides for study design, patient sel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/purple-biotech-reports-positive-nt219-122800847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443382.USD","BK4213","LU2236285917.USD","PDX","LU2456880835.USD","CRC","LU0157215616.USD","LU2237443622.USD","LU2237443978.SGD","LU1496350171.SGD","LU1366192091.USD","LU2417539215.USD","PPBT","LU0456854461.SGD","LU2237443549.SGD","BK4007","LU1366333091.USD","LU0266512127.USD","APC","LU2420271590.USD","LU0077335932.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PDX\",params:#limit:5,,,undefined,":[{"date":"2025-06-12","symbol":"PDX","amount":0.1334,"announcedDate":"2025-06-02","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-12","defaultRemindTime":1749735000000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-12","currency":"USD","dateTimestamp":1749700800000,"payDate":"2025-07-01"},{"date":"2025-05-12","symbol":"PDX","amount":0.1334,"announcedDate":"2025-05-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-12","defaultRemindTime":1747056600000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-02","payableDate":"2025-05-12","currency":"USD","dateTimestamp":1747022400000,"payDate":"2025-06-02"},{"date":"2025-04-11","symbol":"PDX","amount":0.1334,"announcedDate":"2025-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-11","defaultRemindTime":1744378200000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-01","payableDate":"2025-04-11","currency":"USD","dateTimestamp":1744344000000,"payDate":"2025-05-01"},{"date":"2025-03-13","symbol":"PDX","amount":0.1334,"announcedDate":"2025-03-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-13","defaultRemindTime":1741872600000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-13","currency":"USD","dateTimestamp":1741838400000,"payDate":"2025-04-01"},{"date":"2025-02-13","symbol":"PDX","amount":0.1334,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-13","defaultRemindTime":1739457000000,"name":"PIMCO DYNAMIC INCOME STRATEGY FUND","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739422800000,"payDate":"2025-03-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-08","recordDate":"2023-12-11","paymentDate":"2024-01-02","value":0.22,"currency":"USD"},{"executeDate":"2024-03-08","recordDate":"2024-03-11","paymentDate":"2024-04-01","value":0.26,"currency":"USD"},{"executeDate":"2024-04-10","recordDate":"2024-04-11","paymentDate":"2024-05-01","value":0.1133,"currency":"USD"},{"executeDate":"2024-05-10","recordDate":"2024-05-13","paymentDate":"2024-06-03","value":0.1133,"currency":"USD"},{"executeDate":"2024-06-13","recordDate":"2024-06-13","paymentDate":"2024-07-01","value":0.1133,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PDX\",market:\"US\",delay:false,,,undefined,":{}}}